Urinary glycosaminoglycans excretion and the effect of dimethyl sulfoxide in an experimental model of non-bacterial cystitis

Soler, Roberto; Bruschini, Homero; Truzzi, José Carlos; Martins, João Roberto Maciel; Câmara, Niels Olsen Saraiva; Alves, Maria Teresa de Seixas; Leite, Kátia R. M.; Nader, Helena B.; Srougi, Miguel; Ortiz, Valdemar

doi:10.1590/s1677-55382008000400013

Cited by 24 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its lower expression was consistent with a previous study from our group that observed in animal models loss of expression of HS and syndecan on the surface of the urothelium of rats after induction of inflammation with DMSO (9). As shown in the study, it may be results from desquamation of the dysfunctional urothelium.…”

Section: Discussionsupporting

confidence: 92%

“…But one can not assure they are specific to PBS/IC. Variations are described in literature and this topic also remains controversial (9,15,16).…”

Section: Discussionmentioning

confidence: 99%

“…Urine and tissue levels of GAG have been studied in PBS/IC and in animal models but their results are not uniform (2,(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18). Such variation suggests that there is no complete understanding of how and why GAG is produced and degraded in PBS/IC, if GAG expression is the cause or the reaction for PBS/IC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the metabolism of glycosaminoglycans in patients with interstitial cystis

et al. 2014

Self Cite

View full text Add to dashboard Cite

ARTICLE INFO ______________________________________________________________ ______________________Introduction: Painful bladder syndrome/interstitial cystitis (PBS/IC) pathogenesis is not fully known, but evidence shows that glycosaminoglycans (GAG) of bladder urothelium can participate in its genesis. The loss of these compounds facilitates the contact of urine compounds with deeper portions of bladder wall triggering an inflammatory process. We investigated GAG in urine and tissue of PBS/IC and pure stress urinary incontinence (SUI) patients to better understand its metabolism. Materials and Methods: Tissue and urine of 11 patients with PBS/IC according to NIDDK criteria were compared to 11 SUI patients. Tissue samples were analyzed by histological, immunohistochemistry and immunofluorescence methods. Statistical analysis were performed using t Student test and Anova, considering significant when p < 0.05. Results: PBS/IC patients had lower concentration of GAG in urine when compared to SUI (respectively 0.45 ± 0.11 x 0.62 ± 0.13 mg/mg creatinine, p < 0.05). However, there was no reduction of the content of GAG in the urothelium of both groups. Immunofluorescence showed that PBS/IC patients had a stronger staining of TGF-beta, decorin (a proteoglycan of chondroitin/dermatan sulfate), fibronectin and hyaluronic acid. Conclusion: the results suggest that GAG may be related to the ongoing process of inflammation and remodeling of the dysfunctional urothelium that is present in the PBS/IC.

show abstract

Section: Discussionsupporting

confidence: 92%

“…But one can not assure they are specific to PBS/IC. Variations are described in literature and this topic also remains controversial (9,15,16).…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the metabolism of glycosaminoglycans in patients with interstitial cystis

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dimethyl sulfoxide is an FDA approved treatment commonly used, since the sixties, as an intravesical therapy for ulcerative and non-ulcerative IC (49). It has been demonstrated that 50% (v/v) solution of DMSO has an antiinflammatory, reactive oxygen scavenger action and easily crosses membranes.…”

Section: Dimethyl Sulfoxidementioning

confidence: 99%

Reviewing Interstitial Cystitis Models and Treatments: A Focus on the Urothelium

F¹

2017

Razavi Int J Med

View full text Add to dashboard Cite

Context: Interstitial cystitis is a multifactorial chronic and debilitating disease which is commonly associated with pain localized in the bladder region, increased urinary frequency, urgency and nocturia. Due to the high prevalence of pain in the population affected more recently the condition is often referred to as interstitial cystitis / bladder pain syndrome (IC/BPS). Evidence Acquisition: Although IC presents with many different symptoms, researchers have formulated three different theories, which are not mutually exclusive, to explain IC pathology: the first is related to the alteration of the proteoglycan and protein junction composition, structure and presence in the urothelium. The second is an immune induced IC resulting from an increased number of activated mast cells in the bladder internal layers, such as detrusor muscle (DM), and mucosa/submucosa. The third type, which is closely related to the second one, is due to a sensory nerve sensitization as an effect of neurotrophic factors molecule release. Results: Previous classification has been mirrored in the development of various in vitro and in vivo disease models created to mimic IC, as well as in the available therapies used to treat the condition to date. Conclusions: This review will summarize the most recent advances in the field, related to the different causative factors contributing to the development of the condition, the in vivo models used as well as the evidence they provide in advancing our knowledge and their limitations. The focus will be on works reporting on IC in the domain related to alterations in proteoglycans and cellular junction, specifically their composition, structure and appearance in the urothelium, and also discuss present and future therapies. Conclusions: This review will summarize the most recent advances in the field, related to the different causative factors contributing to the development of the condition, the in vivo models used as well as the evidence they provide in advancing our knowledge and their limitations. The focus will be on works reporting on IC in the domain related to alterations in proteoglycans and cellular junction, specifically their composition, structure and appearance in the urothelium, and also discuss present and future therapies.

show abstract

“…Intravesical DMSO relieves pain and voiding symptoms likely via its properties of anti-inflammation and mast cell stabilization [24, 25]. In a protamine sulfate-induced rat cystitis model, intravesical DMSO has also been demonstrated to be effective on treating non-bacterial bladder inflammation [26, 27]. Studies in vitro have further demonstrated that DMSO could inhibit stretch-activated ATP release by bladder urothelial cells from IC/PBS patients [28], relax rabbit bladder detrusor muscle contractility [29], improve rat bladder muscle compliance [30], and increase rat bladder sensory afferent neuron release of nitric oxide [31].…”

Section: Introductionmentioning

confidence: 99%

Intravesical Dimethyl Sulfoxide Inhibits Acute and Chronic Bladder Inflammation in Transgenic Experimental Autoimmune Cystitis Models

Kim

Liu

Chen

et al. 2010

BioMed Research International

View full text Add to dashboard Cite

New animal models are greatly needed in interstitial cystitis/painful bladder syndrome (IC/PBS) research. We recently developed a novel transgenic cystitis model (URO-OVA mice) that mimics certain key aspects of IC/PBS pathophysiology. This paper aimed to determine whether URO-OVA cystitis model was responsive to intravesical dimethyl sulfoxide (DMSO) and if so identify the mechanisms of DMSO action. URO-OVA mice developed acute cystitis upon adoptive transfer of OVA-specific OT-I splenocytes. Compared to PBS-treated bladders, the bladders treated with 50% DMSO exhibited markedly reduced bladder histopathology and expression of various inflammatory factor mRNAs. Intravesical DMSO treatment also effectively inhibited bladder inflammation in a spontaneous chronic cystitis model (URO-OVA/OT-I mice). Studies further revealed that DMSO could impair effector T cells in a dose-dependent manner in vitro. Taken together, our results suggest that intravesical DMSO improves the bladder histopathology of IC/PBS patients because of its ability to interfere with multiple inflammatory and bladder cell types.

show abstract

Urinary glycosaminoglycans excretion and the effect of dimethyl sulfoxide in an experimental model of non-bacterial cystitis

Cited by 24 publications

References 20 publications

Evaluation of the metabolism of glycosaminoglycans in patients with interstitial cystis

Evaluation of the metabolism of glycosaminoglycans in patients with interstitial cystis

Reviewing Interstitial Cystitis Models and Treatments: A Focus on the Urothelium

Intravesical Dimethyl Sulfoxide Inhibits Acute and Chronic Bladder Inflammation in Transgenic Experimental Autoimmune Cystitis Models

Contact Info

Product

Resources

About